Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prostate Cancer Screening in the Fit Chilean Elderly: a Head to Head Comparison of Total Serum PSA versus Age Adjusted PSA versus Primary Circulating Prostate Cells to Detect Prostate Cancer at Initial Biopsy

  • Murray, Nigel P. (Hematology, Medicine, Hospital de Carabineros de Chile) ;
  • Reyes, Eduardo (Urology Service, Hospital DIPRECA) ;
  • Orellana, Nelson (Urology Service, Hospital de Carabineros de Chile) ;
  • Fuentealba, Cynthia (Urology Service, Hospital de Carabineros de Chile) ;
  • Jacob, Omar (Urology Service, Hospital de Carabineros de Chile)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Prostate cancer is predominately a disease of older men, with a median age of diagnosis of 68 years and 71% of cancer deaths occurring in those over 75 years of age. While prostate cancer screening is not recommended for men >70 years, fit elderly men with controlled comorbidities may have a relatively long life expectancy. We compare the use of age related PSA with the detection of primary malignant circulating prostate cells mCPCs to detect clinically significant PC in this population. Materials and Methods: All men undergoing PC screening with a PSA >4.0ng/ml underwent TRUS 12 core prostate biopsy (PB). Age, PSA, PB results defined as cancer/no-cancer, Gleason, number of positive cores and percentage infiltration were registered. Men had an 8ml blood sample taken for mCPC detection; mononuclear cells were obtained using differential gel centrifugation and mCPCs were identified using immunocytochemistry with anti-PSA and anti-P504S. A mCPC was defined as a cell expressing PSA and P504S; a positive test as at least one mCPC detected/sample. Diagnostic yields for subgroups were calculated and the number of avoided PBs registered. Esptein criteria were used to define small grade tumours. Results: A total of 610 men underwent PB, 398 of whom were aged <70yrs. Men over 70 yrs had: a higher median PSA, 6.24ng/ml versus 5.59ng/ml (p=0.04); and a higher frequency of cancer detected 90/212 (43%) versus 134/398 (34%) (p=0.032). Some 34/134 cancers in men <70yrs versus 22/90 (24%) of men >70yrs complied with criteria for active surveillance. CPC detection: 154/398 (39%) men <70yrs were CPC (+), specificity for cancer 86%, sensitivity 88%, 14/16 with a false (-) result had a small low grade PC. In men >70 years, 88/212 (42%) were CPC (+); specificity 92%, sensitivity 87%, 10/12 with a false (-) had small low grade tumours. False (+) results were more common in younger men 36/154 versus 10/88 (p<0.02). With a PSA cutoff of 6.5ng/ml, in men <70yrs, 108 PB would be avoided, missing 56 cancers of which 48 were clinically significant. Using CPC detection, 124 biopsies would be avoided, missing only 2 clinically significant cancers. In men >70 yrs using a PSA >6.5ng/ml would have resulted in 108 PB with 34 PC detected, of which 14(41%) were small low grade tumours. Conclusions: The use of CPC detection in the fit elderly significantly decreases the number of PBs without missing clinically significant cancers, indicating superiority to the use of age-related PSA.

Keywords

References

  1. Alibhai SM, Naglie G, Nam R, et al (2003). Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol, 21, 3318-27 https://doi.org/10.1200/JCO.2003.09.034
  2. Andiole GL, Grubb RL III, Buys SS, et al (2009). Mortality results from a randomized prostate cancer screening trial. NEJM, 360, 1310-19. https://doi.org/10.1056/NEJMoa0810696
  3. Anastasiadis E, van der Meulen J, Emberton M (2014). Hospital admissions after TRUS biopsy of the prostate in men diagnoses with prostate cancer: A database analysis in England. Int J Urol, (in Press).
  4. Beach R, Gown AM, Peralta-Venturina MN et al (2002). P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol, 26, 1588-96. https://doi.org/10.1097/00000478-200212000-00006
  5. Becker D, Ryemon S, Gross J, et al (2014). Cancer trends among the extreme elderly in the era of cancer screening. J Geriatr Oncol, 1, 408-14.
  6. Belbase NP, Agrawal CS, Pokharel PK, et al (2013). Prostate cancer screening in a healthy population cohort in Eastern Nepal: an explanatory trial study. Asian Pac J Cancer Prev, 14, 2835-8. https://doi.org/10.7314/APJCP.2013.14.5.2835
  7. Borgen E, Naume B, Nesland JM, et al (1999). Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells, Cytotherapy, 1, 377-388. https://doi.org/10.1080/0032472031000141283
  8. Bozeman CB, Carver BS, Eastham JA, et al (2002). Treatment of chronic prostatitis lowers serum prostate specific antigen, J Urol, 167, 1723-6. https://doi.org/10.1016/S0022-5347(05)65186-5
  9. Campbell MF, Wein AJ, Kavoussi LR (2011). Campbell's Urology. V, Section II, chapter, 3, 2011.
  10. Carter HB, Albertsen PC, Barry MJ, et al (2013). Early detection of prostate cancer: AUA guideline. J Urol, 190, 419-26 https://doi.org/10.1016/j.juro.2013.04.119
  11. Delongchamps NB, Wang CY, Chandan V, et al (2009). Pathological characteristics of prostate cancer in elderly men. J Urol, 182, 927-30 https://doi.org/10.1016/j.juro.2009.05.018
  12. Droz JP, Aapro M, Balducci L et al (2014). Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol, 15, e404-414. https://doi.org/10.1016/S1470-2045(14)70018-X
  13. Epstein JI, Walsh PC, Carmichael M (1994). Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer, JAMA, 271, 368-74. https://doi.org/10.1001/jama.1994.03510290050036
  14. Fehm T, Solomayer EF, Meng S et al (2005). Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells, Cytotherapy, 7, 171-85. https://doi.org/10.1080/14653240510027082
  15. Ferlay J, Autier P, Bonial M et al (2007). Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol, 18, 581-92
  16. Gandaglia G, Karakiewicz PI, Abdollah F, et al (2014). The effect of age at diagnosis on prostate cancer mortality: A grade for grade and stage for stage analysis. Eur J Surg Oncol, 40, 1706-1715 https://doi.org/10.1016/j.ejso.2014.05.001
  17. Gann PH, Hennekens CH, Stampfer MJ (1995). A prospective evaluation of plasma PSA for detection of prostate cancer. JAMA, 273, 289-94. https://doi.org/10.1001/jama.1995.03520280035036
  18. Heidenrich A, Bastian PJ, Bellmunt J, et al (2012). Guidelines on prostate cancer. Arnhem, Netherlands. European Association of Urology www.eau.org
  19. Jemal A, Siegel R, Ward E et al (2008). Cancer statistics 2008. CA Cancer J Clin, 58, 71-96 https://doi.org/10.3322/CA.2007.0010
  20. Lalitha K, Suman G, Pruthvish S, et al (2012). Estimation of time trends of incidence of prostate cancer: an Indian scenario. Asian Pac J Cancer Prev, 13, 6245-50 https://doi.org/10.7314/APJCP.2012.13.12.6245
  21. Mitsuzuka K, Koie T, Narita S, et al (2014). Late pathological and oncological outcomes of elderly men treated with radical prostatectomy worse than those of younger men? Matched pair analysis between patients aged <70 and >70 years. Jpn J Clin Oncol, 44, 587-92. https://doi.org/10.1093/jjco/hyu038
  22. Moreno JG, Croce CM, Fischer R, et al (1992). Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res, 52, 6110-2
  23. Murray NP, Reyes E, Badinez L, et al (2013), Circulating prostate cells found in men with benign prostate disease are P504S negative: clinical implications, J Oncology, 2013:165014.
  24. Murray NP, Reyes E, Fuentealba C et al. (2014). Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile. Asian Pac J Cancer Prev, 15, 9335-9. https://doi.org/10.7314/APJCP.2014.15.21.9335
  25. Murray NP, Reyes E, Fuentealba C, et al (2014). Primary circulating prostate cells are not detected in low grade small volume prostate cancer. J Oncol, 2014, 612674.
  26. NCCN clinical practical guidelines in oncology: prostate cancer 2014. Available at http://www.nccn.org
  27. Panteleakou Z, Lembessis P, Sourla A et al. (2009), Detection of circulating tumor cells in prostate cancer patients:Methodological pitfalls and clinical relevance, Molecular Medicine, 15, 101-14.
  28. Paterlini-Brechot P, Benali NL (2007). Circulating tumor cells (CTC) detection: Clinical impact and future directions, Cancer Letters, 253, 180-204. https://doi.org/10.1016/j.canlet.2006.12.014
  29. Pavlakis K, Stravodimos K, Kapetanakis T et al (2010). Evaluation of routine application of P504S, 34bE12 and p63 immunostaining on 250 prostate needle biopsy specimens, Internat Urol Nephrol, 42, 325-30. https://doi.org/10.1007/s11255-009-9622-1
  30. Punglia RS, D'Amico AV, Catalona WJ et al (2006). Impact of age, benign prostatic hyperplasia, and cancer on prostatespecific antigen level, Cancer, 106, 1507-13. https://doi.org/10.1002/cncr.21766
  31. Ries LAG, Melbert D, Krapcho M et al (2009). SEER Cancer Statistics Review. 1975-2005 Betheseda MD: National Cancer Institute, 2008. Available at: http://seer.cancer.gov/csr/1975-2005, based on December 2009 SEER data submission.
  32. Rubin MA, Zhou M, Dhanasekaran SM et al (2002). a-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer, JAMA, 287, 1662-70. https://doi.org/10.1001/jama.287.13.1662
  33. Schroder FH, Hugosson J, Roobol MJ, et al (2009). Screening and prostate cancer mortality in a randomized European Study. NEJM, 360, 1320-8. https://doi.org/10.1056/NEJMoa0810084
  34. Situmorang GR, Umbas R, Mochtar CA et al (2012). Prostate cancer in younger and older patients: do we treat them differently? Asian Pac J Cancer Prev, 13, 4577-80 https://doi.org/10.7314/APJCP.2012.13.9.4577
  35. Sun L, Caire AA, Robertson CN, et al (2009). Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late PSA eras. J Urol, 182, 2242-9 https://doi.org/10.1016/j.juro.2009.07.034
  36. Verim L, Yildirim A, Basok ER, et al (2013). Impact of PSA and DRE on histologica findings at prostate biopsy in Turkish men over 75 years of age. Asian Pac J Cancer Prev, 14, 6085-8. https://doi.org/10.7314/APJCP.2013.14.10.6085
  37. Walter LC, Covinsky KE (2001). Cancer screening in elderly patients: a framework for individual decision making. JAMA, 285, 2750-6 https://doi.org/10.1001/jama.285.21.2750
  38. Went PT, Lugli A, Meier S, et al (2004). Frequent EpCam protein expression in human carcinomas. Human Pathology, 35, 122-8. https://doi.org/10.1016/j.humpath.2003.08.026
  39. Zhou M, Chinnaiyan AM, Lleer CG, et al (2002). Alphamethylacyl- CoA racemase: a novel tumor marker overexpressed in several human cancers and their precursor lesions. Am J Surg Pathol, 26, 926-31. https://doi.org/10.1097/00000478-200207000-00012

Cited by

  1. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5365